Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ALMB-0168 in previously treated osteosarcoma
ChiCTR2100046224Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ALMB-0168 in osteosarcoma (OS), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Adverse reactions, Dose-limiting toxicities and 1 more. Started May 2021; status: recruiting.
02
Drugs
ALMB-0168
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2100046224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046224.